Stay updated with breaking news from Jrs pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
U.S. health regulators declined to approve a nasal spray that would have been the first needle-free emergency treatment for allergic reactions and asked for further tests, a move that left its developer ARS Pharmaceuticals "very surprised". ARS Pharma's Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi's Auvi-Q filled with epinephrine, a life-saving drug used by people at risk of anaphylaxis and other allergic reactions. The U.S. Food and Drug Administration (FDA), in its so-called "Complete Response Letter", asked the company to complete a repeat-dose study on the treatment before a potential approval, rather than after as was mutually agreed in August, ARS Pharma said late on Tuesday. ....
Dublin, June 29, 2023 (GLOBE NEWSWIRE) The "Cell based Assays Market by Product & Service (Reagents, Assays Kits, Cell Lines, Microplates, Probes. ....
/PRNewswire/ The "Cell & Gene Therapy Manufacturing Services Market Report 2023" has been added to ResearchAndMarkets.com s offering. The global cell & gene. ....